Use Of Second Generation Tyrosine Kinase Inhibitors For Second-Line Treatment Of Chronic Myeloid Leukemia After Imatinib Failure

dc.contributor.author	Buyukasik, Yahya
dc.date.accessioned	2019-12-10T11:21:09Z
dc.date.available	2019-12-10T11:21:09Z
dc.date.issued	2011
dc.identifier.issn	1306-133X
dc.identifier.uri	https://doi.org/10.4999/uhod.11012
dc.identifier.uri	http://hdl.handle.net/11655/15439
dc.description.abstract	Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments of CML. In Turkey, currently 2nd line TKIs are indicated only for imatinib failure. This review will evaluate indications for changing imatinib with dasatinib or nilotinib, success of the 2nd line agents in the second-line treatment and some important properties of these agents.
dc.language.iso	en
dc.publisher	Akad Doktorlar Yayınevi
dc.relation.isversionof	10.4999/uhod.11012
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Oncology
dc.title	Use Of Second Generation Tyrosine Kinase Inhibitors For Second-Line Treatment Of Chronic Myeloid Leukemia After Imatinib Failure
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.relation.journal	Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi
dc.contributor.department	İç Hastalıkları
dc.identifier.volume	21
dc.identifier.issue	2
dc.identifier.startpage	4
dc.identifier.endpage	9
dc.description.index	WoS
dc.description.index	Scopus